

10/571989

APPROVED FOR 13 MAR 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Michael Kalafatis
FOR : **EXOSITE-DIRECTED THROMBIN
INHIBITORS**
SERIAL NO. : Unknown
FILED : Herewith
EXAMINER : N/A
ART UNIT : Unknown
CONFIRMATION NO. : Unknown
ATTORNEY DOCKET NO. : **CLEV 200023**

INFORMATION DISCLOSURE STATEMENT

MAIL STOP
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, 1.98 and MPEP § 609, applicant(s) submit(s) the following Disclosure Statement concerning art of which the applicant(s) is (are) aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement should not be construed to be an admission that any information referred to herein or submitted herewith is "prior art" or is considered to be material to patentability for this invention.

The United States Patent and Trademark Office OG Notice dated 12 October 2004 published a final rule revising 37 C.F.R. 1.98 dealing with the content of Disclosure Statements. Paragraph (a)(2) was revised to read in part, "A legible copy of: (i) Each foreign patent; (ii) Each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the

Office.” Therefore, Applicant(s) has (have) not enclosed copies of the cited U.S. patents and published patent applications with this Information Disclosure Statement.

In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

☒ Under § 1.98(a)(3), a concise explanation of relevance is required for information that is not in the English language. Accordingly, the English language documents have no further explanation.

☐ All of the cited and/or included documents were cited by the Patent Office in a related application(s). A copy of the Search Report is enclosed.

Consideration of the appropriate paragraph(s) indicated below is respectfully requested:

☒ WITHIN THREE MONTHS OF FILING: Under § 1.97(b)(1), this Information Disclosure Statement is being filed within three months of the filing date of the application (or date of entry of the national stage). Although it is believed no fee is necessary, any deficiency in fees should be handled as set forth below.

☐ BEFORE FIRST OFFICE ACTION: Under § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be handled as set forth below.

☐ BEFORE FINAL ACTION, OR NOTICE OF ALLOWANCE, OR ACTION THAT CLOSES PROSECUTION/WITH STATEMENT: Under § 1.97(c)(1), this information shall be considered if filed before the mailing date of a final action, or a Notice of Allowance or action that otherwise closes prosecution in the application if accompanied by the statement:

Under § 1.97(e)(1), the undersigned states:

☐ A. that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

☐ B. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

☐ **BEFORE FINAL ACTION, OR NOTICE OF ALLOWANCE, OR ACTION THAT CLOSES PROSECUTION/WITH FEE:** Under § 1.97(c)(2), this information shall be considered if filed before the mailing date of a final action if accompanied by a fee in the amount of \$180.00 as required by §1.17(p). Accordingly, the necessary fee accompanies this Information Disclosure Statement, as set forth below.

☐ **AFTER FINAL ACTION, OR NOTICE OF ALLOWANCE, OR ACTION THAT CLOSES PROSECUTION/AND ON OR BEFORE PAYMENT OF THE ISSUE FEE:**

1. Under § 1.97(e)(1), the undersigned states:

☐ A. that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; **or**

☐ B. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement; **and**

2. ☐ the fee in the amount of \$180.00 as required by §1.17(p). Accordingly, the necessary fee accompanies this Information Disclosure Statement, as set forth below.

☐ **PRIORITY CLAIM:** The attached PTO 1449 Form includes all patents, publications, or other information previously cited by or submitted to the Office in one or more prior applications from which the present application claims priority. These one or more prior applications are identified in the papers accompanying the filing of this application.

Any payment due for the filing of this Information Disclosure Statement is authorized to be charged to a Credit Card. The appropriate form PTO-2038 is enclosed for this purpose. **If the Credit Card is unable to be charged, please charge any and all fees or credit any overpayment to Deposit Account No. 06-0308.**

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP



Mark E. Bandy, Reg. No. 35,788
1100 Superior Avenue, Seventh Floor
Cleveland, OH 44114-2579
216-861-5582

March 10, 2006
Date

CERTIFICATE OF MAILING OR TRANSMISSION

I certify that this Information Disclosure Statement and accompanying document(s) are being

- ☐ deposited with the United States Postal Service as First Class mail under 37 C.F.R. 1.8, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.
- ☐ transmitted to facsimile number under 37 C.F.R. 1.8 on the date indicated below.
- ☒ deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10, addressed to: Mail Stop , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Express Mail Label No.: <i>EV 6903781345</i>	Signature <i>Mary Ann Temesvari</i>
Date <i>March 10, 2006</i>	Printed Name Mary Ann Temesvari

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 1A2013071989 13 MAR 2006

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)	Complete if Known	
	Application Number	Unknown 80/571989
	Filing Date	Herewith
	First Named Inventor	Michael Kalafatis
	Art Unit	Unknown
	Examiner Name	N/A
Sheet 1 of 1	Attorney Docket No.	CLEV 200023

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No. Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AA	US-		
	AB	US-		
	AC	US-		
	AD	US-		
	AE	US-		
	AF	US-		
	AG	US-		
	AH	US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code-Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T
	AI				<input type="checkbox"/>
	AJ				<input type="checkbox"/>
	AK				<input type="checkbox"/>
	AL				<input type="checkbox"/>

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T
	AM	HORTIN, G.L., "Sulfation of Tyrosine Residues in Coagulation Factor V. Blood," Vol. 76, No. 5, pp. 946-952, 1990	<input type="checkbox"/>
	AN	BECK, D.O., et al., "The contribution of amino acid region ASP695-TYR698 of factor V to procofactor activation and factor Va function," Journal of Biological Chemistry, Vol. 279, No. 4, pp. 3084-3095, 2004	<input type="checkbox"/>
	AO	PITTMAN, D.D., et al., "Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity," Biochemistry, Vol. 33, No. 22, pp. 6952-6959, 1994	<input type="checkbox"/>
	AP	HORTIN, G.L., et al., "Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates," Journal of Biological Chemistry, Vol. 266, No. 11, pp. 6866-6871, 1991	<input type="checkbox"/>
	AQ	PREVIERO, A., et al., "Specific sulfonation of tyrosine, tryptophan, and hydroxy-amino acids in peptides," Biochimica et Biophysica Acta, Vol. 581, No. 2, pp. 276-282, 1979	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--